AstraZeneca will break ground in early 2015 on its $500 million Global R&D Centre and Corporate Headquarters in Cambridge in the United Kingdom. Providing sophisticated pharmaceutical discovery and development facilities, the project will include space for biologics research, high throughput screening, medicinal chemistry, pre-clinical research, and clinical development. The 11-acre campus will accommodate approximately 2,000 employees.
Bristol-Myers Squibb will build a 323,000-sf biologics manufacturing facility in Dublin, Ireland. Located on the company's existing pharmaceutical production campus, the building will provide open labs and offices, six 15,000-liter bioreactors, and a purification area. The estimated construction cost of the project is $900 million. The facility will accommodate up to 400 employees and is expected to be fully operational in 2019.
Gilead Sciences broke ground in October of 2014 on a $50 million laboratory building in Edmonton, Alberta. Designed by Manasc Isaac Architects, the 44,000-sf facility will accommodate 80 additional employees engaged in pharmaceutical research, development, and production. The construction manager for the project is Graham Group and completion is expected in spring of 2016.
Novo Nordisk began construction in October of 2014 on a $127 million biomedical research facility in Måløv, Denmark, to support the development of treatments for diabetes. Housing 350 employees, the three-story, 177,600-sf project will be built as two laboratory wings connected by a central structure housing offices and an auditorium. Occupancy is expected in early 2016.
The Jackson Laboratory opened the $135 million JAX Genomic Medicine facility in October of 2014 in Farmington, Conn. Located on 17 acres at the University of Connecticut Health Science Center, the four-story, 183,500-sf building features 17 wet labs and 17 dry labs arranged in flexible, collaborative clusters. The facility also provides core service labs, two large conference rooms, offices, a data center, and a 200-seat auditorium.
XBiotech broke ground in September of 2014 on a 46,000-sf pharmaceutical research and manufacturing center in Austin, Texas. The $12 million facility will reach completion in mid-2015 with production of the cancer drug Xilonix commencing in early 2016. The project is part of a $200 million campus that XBiotech plans to develop on the 48-acre site.
Novartis is partnering with the University of Pennsylvania to create the Center for Advanced Cellular Therapeutics. Located on the Penn Medicine Campus in Philadelphia, the 30,000-sf facility will accommodate research on personalized cellular cancer therapies using chimeric antigen receptor technology (CAR). Supported by $20 million in funding from Novartis, the project will be built on top of the Jordan Medical Education Center and South Pavilion Extension, which is currently under construction. Completion is expected in 2016.
Merck broke ground in August of 2014 on a $108 million pharmaceutical manufacturing plant in Nantong, China. Located in the BioSpark development, the 430,560-sf facility will produce therapeutics for the treatment of cardiovascular diseases, thyroid disorders, and diabetes. The highly efficient project is designed to minimize waste during the manufacturing process. Completion is expected in 2016 with commercial operations commencing in 2017.
Queen Elizabeth Hospital is partnering with the University of Birmingham and Birmingham Children’s Hospital to build the $40 million Institute of Translational Medicine. The 64,600-sf clinical research facility will include an early-phase trial unit and a pharmaceutical development hub, as well as housing the Rare Disease Centre. General contractor VINCI Construction was awarded a $17.6 million contract to renovate existing space at the hospital to accommodate the facility. Occupancy is expected in June of 2015.
Parkview Health is building the $20 million Mirro Center for Research and Education in Fort Wayne, Ind. The 82,000-sf translational research facility will accommodate clinical trials for pharmaceutical products and medical devices, as well as housing instructional space and a simulation training suite. The building will provide labs, offices, conference rooms, and an auditorium. Completion is expected in early 2015.
Merck will begin construction in August of 2014 on a 430,000-sf pharmaceutical production plant in Shanghai. The $107 million facility will manufacture drugs for diabetes as well as thyroid and heart conditions. Completion is expected in 2016 and commercial production will begin in 2017.
The Translational Research Institute for Metabolism and Diabetes (TRI) is a unique stand-alone hospital-like facility that offers rare proof that facility design can accelerate the time it takes to go from new lab discovery to patient treatment. Utilizing a core-based model that includes imaging, pharmacy, kitchen, and lab cores in one location, the facility focuses on fast-tracking functional treatments for diabetes and obesity.
Purdue Pharma Manufacturing will build a 188,000-sf production plant in the Treyburn Corporate Park in Durham, N.C. The project will provide cleanrooms with epoxy-coated floors, walls, and ceilings for the manufactucture of oral solid dosage products. The facility will also include offices, labs, conference rooms, and training areas. The general contractor is KBR Building Group. The facility is part of Purdue Pharma's planned $59 million investment in the Durham site over the next three years.
United Therapeutics is planning to build a biomedical R&D facility in Research Triangle Park, N.C. Comprising 250,000 sf of new construction and 150,000 sf of renovated space, the project will provide vivarium space for pigs and xenotransplantation research laboratories. The facility will enable the creation of genetically modified pig embryos which grow to be born with human lungs that can be harvested for transplants and tissue grafts.
NanoViricides has completed its pharmaceutical manufacturing facility in Shelton, Conn. Designed by Id3A, the renovation project created research labs, offices, and cGMP cleanroom suites for the production of active pharmaceutical ingredients (APIs) in an existing 18,000-sf facility. MPH Engineering was the project manager and engineering consultant. Construction began on the facility in August of 2013 and validation commenced in June of 2014.
